Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05566041 · ClinicalTrials.gov registry record · Phase 3
A Phase 3, Controlled, Open-label, Global Randomized Study of RRx-001 With a Platinum Doublet or a Platinum Doublet in Small Cell Lung Cancer
A Phase 3 study of Carcinoma, Small Cell Lung, sponsored by EpicentRx.
- Active
- Registry status
- Phase 3
- Development phase
- 292
- Enrollment target
- 2
- Study locations
NCT05566041: Active Phase 3 study of Carcinoma, Small Cell Lung, sponsored by EpicentRx.
NCT05566041 is a Phase 3 study of Carcinoma, Small Cell Lung that is active but no longer recruiting, run by EpicentRx. The registered enrollment target is 292 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (62% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05566041, a Phase 3 study of Carcinoma, Small Cell Lung, is active but no longer recruiting, sponsored by EpicentRx.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 292 participants
- Enrollment target
- 2
- Study locations
Study Summary
This Global Phase 3 study aims to find out whether RRx-001 + platinum chemotherapy is more effective than platinum chemotherapy alone in 3rd line or beyond small cell cancer.
Primary Outcome
To compare the co-primary efficacy endpoints comprising progression free survival (PFS) and overall survival (OS). PFS is defined as the time from randomization until disease progression or all-cause mortality between the two arms. Disease progression is assessed by the blinded independent central review (BICR) via RECIST 1.1, and is the basis for the principal definition of PFS. OS is defined as the time from randomization to all-cause mortality
Conditions Studied
Interventions
- DRUG RRx-001 + eLOOP Device
- DRUG Cisplatin/carboplatin plus etoposide
Study Locations (2)
Florida
- H. Lee Moffitt Cancer Center & Research Institute, Inc. - Tampa
Kansas
- The University of Kansas Cancer Center - Westwood
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 292 participants |
| Start Date | 2022-08-01 |
| Est. Completion | 2025-12-31 |
| Phase | Phase 3 |
What the registry record for NCT05566041 still lists
NCT05566041 is an interventional study that assigns participants to a tested intervention. The registered 292 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (62% lower).
The record links to 1 condition, with Carcinoma, Small Cell Lung appearing as the primary indexed condition, and to 2 interventions - of which RRx-001 + eLOOP Device is the first listed.
NCT05566041 reports a single indexed study location in Florida, Kansas.
Frequently Asked Questions
What is clinical trial NCT05566041 about?
NCT05566041 is a clinical study titled "A Phase 3, Controlled, Open-label, Global Randomized Study of RRx-001 With a Platinum Doublet or a Platinum Doublet in Small Cell Lung Cancer". This Global Phase 3 study aims to find out whether RRx-001 + platinum chemotherapy is more effective than platinum chemotherapy alone in 3rd line or beyond small cell cancer.
What is the current status of trial NCT05566041?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 292 participants. The study started on 2022-08-01. Estimated completion is 2025-12-31.
What conditions does trial NCT05566041 study?
This clinical trial studies the following conditions: Carcinoma, Small Cell Lung.
What interventions are being tested in trial NCT05566041?
The interventions under investigation include: RRx-001 + eLOOP Device (DRUG), Cisplatin/carboplatin plus etoposide (DRUG).
Who is sponsoring clinical trial NCT05566041?
This trial is sponsored by EpicentRx, which has 15 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05566041 being conducted?
This trial has 2 study locations across Florida, Kansas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05566041's enrollment target sits among peer trials
292 1167th of 2000 higher than 833 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04429542 · 292 participants · Phase 1
Study of Safety and Tolerability of BCA101 Monotherapy and in Combination Therapy in Patients With EGFR-driven Advanced Solid Tumors
- NCT05406622 · 292 participants · NA
MOTIV BTK Randomized Controlled Trial
- NCT05757102 · 292 participants · Phase 3
A Study to Compare the Efficacy, Safety and Tolerability of FF/UMEC/VI With FF/VI in 12-17-year-olds With Asthma
- NCT06569667 · 292 participants · NA
Using AI and Peer Coaching to Address Racial Disparities Among People Who Use Opioids
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI